Myeloproliferative neoplasms trials in Spain

In Spain 28 Also abroad 210

28 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Where
Alicante, Barcelona, Donostia, Girona, Las Palmas De Gran Canaria, Leon, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca
Age
18 years and over
People
460 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07357727 · EU 2025-523555-66-00
Phase 4Taking people
Asciminib Roll-over Study
Where
Badalona, Barcelona, Bilbao, L'Hospitalet de Llobregat, Madrid, Santa Cruz de Tenerife, Santiago de Compostela, Sevilla, Valencia
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
Phase 3Taking people
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Where
Badalona, Barcelona, Las Palmas De Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Salamanca, Valencia
Age
18 years and over
People
324 worldwide
Run by
Takeda
See details and how to joinNCT07623161 · EU 2026-525660-17-00
Phase 3Taking people
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
Where
Alicante, Barcelona, Bilbao, Las Palmas de Gran Canaria, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Palma, Salamanca, Santiago de Compostela, Valencia, Zaragoza
Age
18 years and over
People
426 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07623200 · EU 2026-525398-38-00
Phase 1Taking people
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Where
Badalona, Valencia
Age
18 years and over
People
300 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06150157 · EU 2023-505584-36-00
Phase 2Taking people
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Where
Badalona, Barcelona, Las Palmas De Gran Canaria, Madrid, Málaga, Valencia
Age
18 years and over
People
68 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06517875 · EU 2024-518225-15-00
Phase 1Taking people
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Where
Badalona, Las Palmas de Gran Canaria, Madrid
Age
18 years and over
People
218 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07441694 · EU 2026-525217-31-00
Phase 3Taking people
INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)
Where
Badalona, Barakaldo, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Pamplona, Salamanca, Santiago de Compostela, Terrassa, Valencia
Age
18 years and over
People
250 worldwide
Run by
Ono Pharmaceutical Co., Ltd.
See details and how to joinNCT07429266 · EU 2025-524669-25-00
Phase 1Taking people
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Where
Barcelona, Madrid, Málaga, Valencia
Age
18 years and over
People
100 worldwide
Run by
Prelude Therapeutics Incorporated
See details and how to joinNCT07469891 · EU 2026-525484-40-00
Phase 1Taking people
A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)
Where
Barcelona, Madrid
Age
18 years and over
People
256 worldwide
Run by
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
See details and how to joinNCT06343805 · EU 2025-522033-64-00
Phase 1/2Taking people
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Where
Badalona, Salamanca, Valencia
Age
18 years and over
People
240 worldwide
Run by
Sumitomo Pharma America, Inc.
See details and how to joinNCT04176198 · EU 2022-502597-16-00
Phase 2Taking people
Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
Where
Barcelona, Jerez de la Frontera, Las Palmas De Gran Canaria, Madrid, Murcia, Salamanca, Valencia
Age
18 years and over
People
30
Run by
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
See details and how to joinNCT07394153 · EU 2025-522509-39-00
Phase 2Taking people
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
Where
Badalona, Cáceres, Girona, Las Palmas De Gran Canaria, Murcia, Oviedo, Salamanca, Valencia
Age
18 years and over
People
38 worldwide
Run by
Karyopharm Therapeutics Inc.
See details and how to join2024-511309-47-00 · EU 2024-511309-47-00
Phase 2Enrolling by invitation
RVU120 Rollover Study
Where
Pamplona
Age
18 years and over
People
14 worldwide
Run by
Ryvu Therapeutics SA
See details and how to joinNCT06987058 · EU 2025-521673-14-00
Phase 2Taking people
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Where
Barcelona, Madrid
Age
18 years and over
People
140 worldwide
Run by
Cogent Biosciences, Inc.
See details and how to joinNCT04996875 · EU 2024-511407-42-00
Phase 3Taking people
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
Where
Badalona, Barcelona, Las Palmas De Gran Canaria, L'Hospitalet de Llobregat, Madrid, Málaga, Palma, Salamanca, Valencia, Zaragoza
Age
18 years and over
People
126 worldwide
Run by
Kartos Therapeutics Inc.
See details and how to join2023-504724-25-00 · EU 2023-504724-25-00
Phase 1/2Taking people
A Study of BGB-11417 in Participants With Myeloid Malignancies
Where
Barcelona, Salamanca, Sevilla, Valencia
Age
18 years and over
People
260 worldwide
Run by
BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00
Phase 1/2Taking people
A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED)
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Salamanca
Age
18 years and over
People
27 worldwide
Run by
iOnctura SA
See details and how to join2024-515252-20-00 · EU 2024-515252-20-00
No phaseTaking people
Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
Where
Barcelona, Madrid
Age
18 years to 100 years
People
617 worldwide
Run by
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
See details and how to joinNCT06533813
No phaseTaking people
A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes
Where
Barcelona, Madrid
Age
18 years to 100 years
People
678 worldwide
Run by
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
See details and how to joinNCT07203768
Phase 3Taking people
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Where
Barakaldo, Barcelona, Madrid, Oviedo, Salamanca, Seville, Valencia
Age
18 years and over
People
665 worldwide
Run by
Celgene
See details and how to joinNCT04064060
Phase 1/2Taking people
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
Where
Barcelona, Madrid, Salamanca
Age
18 years and over
People
26 worldwide
Run by
iOnctura
See details and how to joinNCT06887803
Phase 2Taking people
Phase 2 Study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea.
Where
Barcelona, Jerez de la Frontera, Las Palmas De Gran Canaria, Murcia, Santiago de Compostela
Age
18 years and over
People
36
Run by
Oryzon Genomics S.A.
See details and how to join2025-523864-19-00 · EU 2025-523864-19-00
Phase 3Taking people
Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera
Where
Alicante, Badalona, Madrid, Málaga, Valencia
Age
18 years and over
People
220 worldwide
Run by
Italfarmaco
See details and how to joinNCT06093672 · EU 2022-502276-23-00
Phase 2Taking people
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
Where
Badalona, Cáceres, El Palmar, Girona, Las Palmas de Gran Canaria, Oviedo, Salamanca, Valencia
Age
18 years and over
People
58 worldwide
Run by
Karyopharm Therapeutics Inc
See details and how to joinNCT05980806